Humedix

Humedix specializes in single-use, disposable medical devices primarily for intravenous (IV) therapy. Their portfolio includes IV cannulas and extension sets, such as the Elravie Ultra Volume Plus (for high-volume infusions), Elravie Light Plus (for smaller-volume applications), and Elravie Deep Line Plus (for specialized use). The HYACLON ONE and HUMIA are also part of their range, likely serving as foundational components for IV administration.

Humedix is based in South Korea. While the country of origin doesn’t directly determine regulatory classification, their devices are listed in the EU’s eudamed database, meaning they comply with the EU Medical Device Regulation (MDR). All listed devices fall under EU Class III classification, which is the highest risk category for medical devices, requiring strict regulatory oversight to ensure safety and performance.

Humedix’s devices are registered in the EU’s eudamed database, which is the official EU portal for medical device information. Registration in eudamed is mandatory under the EU Medical Device Regulation (MDR) and ensures transparency about the manufacturer, device details, and compliance status. This helps healthcare professionals, regulators, and authorities verify the legitimacy and regulatory standing of the devices.

Humedix’s devices are classified as EU Class III because they are considered high-risk medical devices. This classification is determined by factors such as the device’s intended use, potential risks to patients, and the body’s interaction with the product. Class III devices, like those in Humedix’s portfolio, require rigorous clinical evaluation, stringent manufacturing controls, and comprehensive post-market surveillance to ensure safety and efficacy.

The EU Class III classification means Humedix’s devices undergo the highest level of regulatory scrutiny, including detailed risk assessments, clinical trials, and post-market monitoring. This classification ensures that these devices meet strict safety and performance standards before entering the market. For healthcare providers, this classification signals that the devices have undergone thorough evaluation to minimize risks, particularly in critical applications like IV therapy where patient safety is paramount.